贝瑞基因（000710）8月14日主力资金净流出4199.23万元

Group 1 - The core viewpoint of the article highlights the financial performance and stock market activity of Berry Genomics (000710) as of August 14, 2025, indicating a decline in stock price and significant net outflow of funds [1][3] - Berry Genomics reported total revenue of 218 million yuan for Q1 2025, representing a year-on-year decrease of 22.08%, and a net profit attributable to shareholders of 6.46 million yuan, down 178.47% year-on-year [1] - The company's liquidity ratios are strong, with a current ratio of 2.526 and a quick ratio of 2.180, while the debt-to-asset ratio stands at 29.63% [1] Group 2 - Berry Genomics has made investments in 12 companies and participated in 4 bidding projects, along with holding 6 administrative licenses [2]